HomeCompareSSUS vs JNJ

SSUS vs JNJ: Dividend Comparison 2026

SSUS yields 0.54% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SSUS wins by $405.00 in total portfolio value
10 years
SSUS
SSUS
● Live price
0.54%
Share price
$46.70
Annual div
$0.25
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.4K
Annual income
$55.68
Full SSUS calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — SSUS vs JNJ

📍 SSUS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSSUSJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SSUS + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SSUS pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSUS
Annual income on $10K today (after 15% tax)
$45.70/yr
After 10yr DRIP, annual income (after tax)
$47.33/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $656.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSUS + JNJ for your $10,000?

SSUS: 50%JNJ: 50%
100% JNJ50/50100% SSUS
Portfolio after 10yr
$20.2K
Annual income
$441.73/yr
Blended yield
2.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SSUS
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSUS buys
0
JNJ buys
0
No recent congressional trades found for SSUS or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSSUSJNJ
Forward yield0.54%3.36%
Annual dividend / share$0.25$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$20.4K$20.0K
Annual income after 10y$55.68$827.78
Total dividends collected$548.00$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SSUS vs JNJ ($10,000, DRIP)

YearSSUS PortfolioSSUS Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,754$53.77$10,676$355.77+$78.00SSUS
2$11,561$54.04$11,407$389.39+$154.00SSUS
3$12,424$54.29$12,198$426.53+$226.00SSUS
4$13,348$54.53$13,056$467.62+$292.00SSUS
5$14,337$54.75$13,987$513.12+$350.00SSUS
6$15,396$54.96$14,998$563.56+$398.00SSUS
7$16,529$55.16$16,098$619.52+$431.00SSUS
8$17,741$55.34$17,295$681.69+$446.00SSUS
9$19,039$55.52$18,599$750.82+$440.00SSUS
10$20,427$55.68$20,022$827.78+$405.00SSUS

SSUS vs JNJ: Complete Analysis 2026

SSUSStock

The fund is considered a "fund of funds" that, under normal market conditions, seeks to achieve its investment objective by principally investing in unaffiliated equity exchange traded funds ("ETFs") that track the performance of the individual sectors ("Sectors") of the S&P 500 Index. The Advisor will attempt to enhance returns relative to the index by overweighting and underweighting its exposure to the Sectors relative to the index and may reduce its overall exposure to ETFs as determined by its risk management model. It is non-diversified.

Full SSUS Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this SSUS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSUS vs SCHDSSUS vs JEPISSUS vs OSSUS vs KOSSUS vs MAINSSUS vs ABBVSSUS vs MRKSSUS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.